Page 6,556«..1020..6,5556,5566,5576,558..6,5706,580..»

Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Posted: Published on September 1st, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery … Continue reading →

Comments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Posted: Published on September 1st, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery … Continue reading →

Posted in Cell Therapy | Comments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Stribild: High cost of new HIV drug may not be worth the benefit

Posted: Published on September 1st, 2012

Efavirenz, compound in Atripla Credit: Fvasconcellos via Wikimedia Commons Gilead Sciences announced on Monday that Stribild, a four-in-one combination HIV treatment in a single pill, received FDA approval. In clinical trials submitted to the FDA, the drug was found to be as effective as Atripla and has the advantage of fewer side effects. But Stribild has a substantially higher price than current HIV combination drugs. Gileads stated wholesale price of Stribild as $28,500 per patient, per year has created controversy since before its release. Democratic members of Congress sent a letter to dated August 1 urging Gilead to use sustainable pricing that would not burden the AIDS Drug Assistance Program. Andrew Weinstein, president of AHF, stated to the New York Times that Gileads pricing of Stribild shockingly irresponsible. Gilead maintains that Stribild pricing is comparable to other HIV medications on the market. Stribild is priced at 39 percent higher than Complera, a three-drug HIV regimen approved only one year ago.At the time of Compleras approval, there were concerns about the $20,500 wholesale cost of Atripla, which is marketed by Gilead and Bristol-Myers Squibb. HIV drug prices have increased substantially, even during the current economic downturn. Atripla, a combination therapy released … Continue reading →

Posted in Drug Side Effects | Comments Off on Stribild: High cost of new HIV drug may not be worth the benefit

Research and Markets: Neuroprotection – Drugs, Markets and Companies – Updated 2012 Report

Posted: Published on September 1st, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/vrslm2/neuroprotection) has announced the addition of Jain PharmaBiotech's new report "Neuroprotection - Drugs, Markets and Companies" to their offering. This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products. Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as well as retinal degeneration. Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating … Continue reading →

Posted in Drugs | Comments Off on Research and Markets: Neuroprotection – Drugs, Markets and Companies – Updated 2012 Report

P116m in drugs to be torched

Posted: Published on September 1st, 2012

P116m in drugs to be torched BAME PIET Staff Writer The drugs were procured during financial years 2004/05, 2005/06, 2006/07, 2007/08 and 2008/09. Mmegi can reveal that another batch of medicines worth P55 million procured during financial years 2009 to 2012/13 is also waiting to be destroyed once the first lot has been torched. Said the Assistant Minister of Health, Gaotlhaetse Matlhabaphiri, in an exclusive interview with Mmegi yesterday: "The system is such that drugs are not destroyed annually. We still have the expired drugs from September 2004 to September 2009 waiting to be destroyed, and a formal approval has been released (for P55 million worth of drugs for the period September 2009 to June 2012)." Minister Matlhabaphiri explained that the WHO standards allow for up to five percent of procured drugs to expire and be destroyed. He said there are instances where government is obliged to have drugs for certain diseases such as swine flu, malaria, rabbies, anti-vernom and special diseases or conditions in stock. "We have to have those drugs in stock. We might have, for instance, anti-vernom drugs and very few cases of snakebite so that the drugs then remain unused. But we can't send them back … Continue reading →

Posted in Drugs | Comments Off on P116m in drugs to be torched

CVS Caremark Charitable Trust and CVS/pharmacy Provide Much-Needed Support for Hurricane Isaac Relief Efforts

Posted: Published on September 1st, 2012

WOONSOCKET, R.I., Aug. 31, 2012 /PRNewswire/ -- The CVS Caremark Charitable Trust and CVS/pharmacy today announced a donation of more than $20,000 in support of communities that have been affected by Hurricane Isaac. The CVS Caremark Charitable Trust has donated $15,000 to the American Red Cross to support relief and recovery efforts. CVS/pharmacy is also providing nearly 1,000 much-needed first aid kits and nearly $5,000 in additional financial support to Red Cross shelters across Louisiana and Mississippi. (Logo: http://photos.prnewswire.com/prnh/20101221/NE20875LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100816/NE50800LOGO ) Almost allCVS/pharmacy stores in Louisiana and Mississippi are now open. Only six stores are currently closed and theywill reopen as soon as safely possible. To find a nearby CVS/pharmacy, call 1-800-SHOP-CVS or visit the store locator at http://www.cvs.com or m.cvs.com. "Hurricane Isaac has impacted many of the communities we serve in Louisiana and Mississippi," said Eileen Howard Boone, Senior Vice President of Corporate Communications and Community Relations for CVS Caremark. "We are committed to supporting relief efforts in these communities and we hope our customers and colleagues in affected areas can safely return home soon." The Company is also supporting its employees who have been affected by the hurricane through the CVS Caremark Employee Relief Fund. Launched … Continue reading →

Posted in Pharmacy | Comments Off on CVS Caremark Charitable Trust and CVS/pharmacy Provide Much-Needed Support for Hurricane Isaac Relief Efforts

Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Posted: Published on August 31st, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Posted: Published on August 31st, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery … Continue reading →

Comments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the …

Posted: Published on August 31st, 2012

NEWARK, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that Armin Curt, MD, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University Hospital, University of Zurich, and principal investigator for the Company's Phase I/II clinical trial in chronic spinal cord injury, will make an oral presentation on the progress of the trial on Monday, September 3 at the 51st Annual Scientific Meeting of the International Spinal Cord Society (ISCOS), which is being held in London, England, on September 3-5, 2012. In his presentation, Dr. Curt will present six-month interim data from the first patient cohort in the trial. The three patients in the first cohort all have thoracic (chest-level) spinal cord injury classified as AIS A, in which there is no neurological function below the injury level. The second and third cohorts will be patients classified as AIS B and AIS C, those with less severe injury, in which there is some preservation of sensory or motor function. In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor function and bowel/bladder function. The trial is being conducted at Balgrist University Hospital, … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the …

New malaria drug excites

Posted: Published on August 31st, 2012

Lastman Muthko lies at a Mdecins Sans Frontires hospital in the Upper Nile in South Sudan in July.(Nichole Sobecki, AFP) A single anti-malarial pill with no side effects that blocks transmission of the killer disease could soon be available, University of Cape Town scientists announced this week. Based on a recently discovered chemical compound, the cure could deal with many of the shortcomings that have prevented an effective treatment for the infectious disease that, according to the World Health Organisation, kills a child in Africa every minute. Professor Kelly Chibale, project leader at the universitys Drug Discovery and Development Centre, said very low doses of the treatment had proved effective in animal tests. It was now ready for preclinical development and human clinical trials were expected to start next year. A new drug was needed because the treatments currently available have shortcomings that range from negative side effects to resistance and noncompliance, he said. Our compound has the potential to kill off a number of drug-resistant strains of malaria in Africa and Asia, as well as improve compliance, given the potential single-dose administration. Named the MMV390048 molecule, the compound was designed, synthesised and evaluated in a record 18 months in … Continue reading →

Posted in Drug Side Effects | Comments Off on New malaria drug excites

Page 6,556«..1020..6,5556,5566,5576,558..6,5706,580..»